여성 불임 : 역학 예측(-2033년)

Infertility is a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 or more months of regular unprotected sexual intercourse (Zegers-Hochschild et al., 2009; Mascarenhas et al., 2012; Mayo Clinic, 2021; World Health Organization, 2024). Infertility affects millions of people and has an impact on their families and communities. Estimates suggest that approximately one in every six people of reproductive age worldwide experience infertility in their lifetime (World Health Organization, 2024). There are two types of infertility. Primary infertility refers to when a woman has never conceived despite cohabitation, unprotected sexual intercourse, and the wish to become pregnant for at least 12 months. Secondary infertility refers to when a woman has previously conceived but was subsequently unable to conceive despite cohabitation, unprotected sexual intercourse, and the wish to become pregnant for at least 12 months (Zegers-Hochschild et al., 2009; Mascarenhas et al., 2012). In the female reproductive system, infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, among others (Mayo Clinic, 2021; World Health Organization, 2024).

A considerable proportion of women of reproductive age experience infertility. Infertility generally refers to a difficulty in becoming pregnant after trying to conceive for one year, whereas impaired fecundity includes problems either in becoming pregnant or carrying a pregnancy to term (Chandra, Copen and Stephen, 2014). The major causative factors of infertility and impaired fecundity are fallopian tube dysfunction, disorders of menstruation, sexual disorders, increasing age, and in a very small percentage of patients, ovarian failure. Although infertility is more prevalent in recent times, the use of advanced assisted reproductive technologies in modern medicine greatly increases the chances of solving infertility problems (Roupa et al., 2009).

Multiple factors have been identified as possible contributors to fertility problems in women, including socio-demographic, behavioral, physical, and mental health conditions. Some risk factors affecting fertility cannot be changed, while others such as lifestyle choices may be altered. Many of the behavioral factors and health conditions may be preventable, such as smoking, obesity, and diabetes. Certain races or ethnicities, socioeconomic status, access to care, and use of infertility services/treatments were also noted as factors tied to a higher prevalence of female infertility (Crawford et al., 2017).

In the 7MM, the diagnosed incident cases of female infertility are expected to decrease from 420,793 cases in 2023 to 408,771 cases in 2033, at a negative annual growth rate (AGR) of 0.29%. In 2033, the US will have the highest number of diagnosed incident cases of female infertility in the 7MM, with 139,027 diagnosed incident cases, whereas Spain will have the fewest diagnosed incident cases with 26,859 cases.

In the 7MM, the total prevalent cases of female infertility are expected to decrease from 16,732,165 cases in 2023 to 16,053,363 cases in 2033, at a negative AGR of 0.41%. In 2033, the US will have the highest number of total prevalent cases of female infertility in the 7MM, with 5,492,669 cases, whereas Spain will have the fewest cases with 1,009,964 total prevalent cases. GlobalData epidemiologists attribute the changes in the diagnosed incident cases and total prevalent cases to the underlying demographic changes in the respective markets.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for female infertility in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of female infertility, total prevalent cases of female infertility, and total prevalent cases of impaired fecundity. The diagnosed incident and total prevalent cases of female infertility and total prevalent cases of impaired fecundity are further segmented by age (15-24 years, 25-34 years, and 35-44 years). Additionally, this report provides the total prevalent cases of female infertility by major etiological factors (endometriosis, fallopian tube abnormalities, hormonal/metabolic disorders, ovulatory dysfunction disorders, uterine abnormalities, and unexplained factors). This epidemiology forecast for female infertility is supported by historical data obtained from peer-reviewed articles and population-based studies. GlobalData epidemiologists used the clinical definition of female infertility given by the World Health Organization (WHO) to assess the total prevalence of female infertility across the 7MM. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident and total prevalent cases of female infertility across these markets.

Reasons to Buy

The Female Infertility epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global Female Infertility market.
• Quantify patient populations in the global Female Infertility market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Female Infertility therapeutics in each of the markets covered.

Table of Contents

Table of Contents

1 Female Infertility: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 Forecast assumptions and methods: diagnosed incident cases of female infertility.
  • 2.4.4 Forecast assumptions and methods: total prevalent cases of female infertility.
  • 2.4.5 Forecast assumptions and methods: total prevalent cases of impaired fecundity.
  • 2.4.6 Forecast assumptions and methods: total prevalent cases of female infertility by major etiologic factors.
• 2.5 Epidemiological forecast for female infertility and impaired fecundity (2023-33)
  • 2.5.1 Diagnosed incident cases of female infertility.
  • 2.5.2 Age-specific diagnosed incident cases of female infertility
  • 2.5.3 Total prevalent cases of female infertility
  • 2.5.4 Age-specific total prevalent cases of female infertility
  • 2.5.5 Total prevalent cases of female infertility by major etiologic factors
  • 2.5.6 Total prevalent cases of impaired fecundity
  • 2.5.7 Age-specific total prevalent cases of impaired fecundity
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact.
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us